A run of items this week about the same underlying problem: the tools meant to check our work are themselves unreliable, and the bill for using them is coming due.
Your review pipeline is drifting with the conversation’s mood
If your team runs promotional copy, clinical summaries or MLR-prep outputs through an LLM in a single conversation thread, the scores are being skewed by whatever came before — negative items more than positive, by a factor of 1.6. The fix is unglamorous and effective: a fresh context for every item. Most off-the-shelf review workflows don’t do this, which means the more you batch, the less you can trust the output.
A third of medical chatbots breach their own safety thresholds
A systematic sweep of 6,233 medical GPTs found that a third or more violate operational safety thresholds, and over half of the action-enabled ones carry no privacy disclosures. These are exactly the numbers regulators and legal teams will reach for. If you are advising a client on deploying an AI-assisted medical information tool, you now have an audit framework — and a set of findings — to point at when the question of due diligence comes up.
The FDA is piloting AI in early-phase trials
The agency’s request for information on AI-enabled optimisation of early-phase trials is worth reading not for what it decides — it decides nothing yet — but for how it frames the questions. This is an early look at how the FDA will think about AI in the trial process, and by extension the communications around it. The thinking that shapes the guidance is happening now, in the open.
Ogilvy Health puts its AI strategy on the record
Ogilvy Health has gone public on its adoption pace, its nano-influencer plans and its own proprietary bot, ‘Ria’. Read it as a competitive benchmark, not a playbook: the tool is agency-owned and won’t transfer to an in-house team. What does transfer is the signal about where a large healthcare agency is willing to say, on the record, that it is placing its bets.
The AI upsell is coming at renewal
If your operation runs on Salesforce or a Veeva-adjacent stack, the AI add-on costs land at your next renewal whether you wanted them or not — and Gartner is already warning that enterprise agreements may not hold. For any communications operation whose budget predictability depends on its CRM, this is a line item to raise before it raises itself.